Alberto Mello e Silva , Hospital da Luz specialist in Cardiology and Internal Medicine (in the units of Amadora, Oeiras and Torres de Lisboa), is one of the co-authors of the practical guidance of the European Society of Atherosclerosis , concerning the combined therapies to use in the treatment and control of atherosclerosis in patients with high and very high cardiovascular risk. Cardiovascular diseases are the main cause of death in Portugal, atherosclerosis being the most common underlying physio-pathological process, which consists in the formation of fat plaques in the arteries, hindering the passage of blood. In 2019, the European Society of Atherosclerosis published a document with guidelines for combined therapy in the control of high levels of cholesterol in low density lipoproteins (C-LDL) and / or triglyceride, in patients with high and very high cardiovascular risk. In view of the arising difficulties and doubts as to the application of these guidelines, the Society appointed a task force of 18 specialists from all over Europe, to establish practical guidance that was published last March. “This is a revision based on evidence and aiming to enhance the therapy combined with medication commonly used in the treatment of dyslipidemia and in the control of cholesterol levels in real life, in order to reduce the risk of cardiovascular events”, explains Alberto Mello e Silva. Former president of the Portuguese Society of Atherosclerosis, Alberto Mello e Silva is a member of the Executive Committee of the European Regional Federation, of the International Society of Atherosclerosis. “Practical guidance for combination lipid-modifying therapy in high- and very-high-risk patients: A statement from a European Atherosclerosis Society Task Force”
